Completed

A Prospective, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of the Safety and Efficacy of Clarithromycin for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients With CD4 Counts <= 100 Cells/mm3

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Clarithromycin

Drug
Who is being recruted

Blood-Borne Infections+13

+ Urogenital Diseases

+ Genital Diseases

Over 12 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: November 1992
See protocol details

Summary

Principal SponsorAbbott
Last updated: January 16, 2015
Sourced from a government-validated database.Claim as a partner

Study start date: November 1, 1992

Actual date on which the first participant was enrolled.

To determine whether clarithromycin is safe and effective in preventing disseminated Mycobacterium avium Complex in HIV-infected patients with CD4 counts <= 100 cells/mm3.

NCT00002336
Principal SponsorAbbott
Last updated: January 16, 2015
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 12 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSlow Virus DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsAcquired Immunodeficiency SyndromeHIV Infections

Criteria

Inclusion Criteria Patients must have: HIV infection. CD4 count <= 100 cells/mm3. No evidence of MAC. Life expectancy of at least 6 months. Exclusion Criteria Concurrent Medication: Excluded: Certain restricted drugs (details not available). Patients with the following prior conditions are excluded: History of allergy or hypersensitivity to macrolides. Active substance abuse or other conditions that would affect study compliance.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 22 locations

Univ of Arizona / Health Science Ctr

Tucson, United StatesOpen Univ of Arizona / Health Science Ctr in Google Maps

California Med Research Group

Fresno, United States

HIV Research Group

San Diego, United States

Saint Francis Mem Hosp

San Francisco, United States
Completed22 Study Centers